加载中
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
收盘时
US$9.27
−US$0.51 · -5.21%
盘后
US$9.2513
−US$0.0187 · -0.20%
10月13日 19:58 ET
盘中时间采用ET。市场数据可能有所延迟。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日内区间
当前US$9.27
52周区间
当前US$9.27
盘中时间采用ET。市场数据可能有所延迟。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日内区间
当前US$9.27
52周区间
当前US$9.27
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 12.5万 USD | 12.5万 USD |
| 毛利 | — | — | — | 12.5万 USD | 12.5万 USD |
| 研究与开发 | 3049.6万 USD | 1931.4万 USD | 2450.6万 USD | 2078.7万 USD | 1517.8万 USD |
| 销售、一般及管理费用 | 1777万 USD | 1405.7万 USD | 1388.5万 USD | 1406万 USD | 1067.3万 USD |
| 营业费用 | 4826.6万 USD | 3337.1万 USD | 3839.1万 USD | 3479.9万 USD | 2585.1万 USD |
| 利息收入 | 391.5万 USD | 108.6万 USD | 208.1万 USD | 121.8万 USD | — |
| 利息支出 | 211.9万 USD | 209万 USD | 259.5万 USD | 170.8万 USD | — |
| 折旧和摊销 | 84.5万 USD | 99万 USD | 96万 USD | 77.8万 USD | 23.2万 USD |
| 营业利润 | −4826.6万 USD | −3337.1万 USD | −3839.1万 USD | −3467.4万 USD | −2572.6万 USD |
| 净利润 | −3818.2万 USD | −5517.7万 USD | −3793.9万 USD | −1879.4万 USD | −3612.4万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.50
上涨空间 142.72%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2572.22万0.00%2.3万亿 USD0.03%US$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI2223.16万0.22%102.75亿 USD0.35%US$146.8-3.04%
iShares Russell 2000 ETFIWM1606.91万0.02%777.48亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF871.64万0.01%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO529.41万0.04%137.9亿 USD0.24%US$351.1-0.74%
Vanguard Russell 2000 ETFVTWO476.51万0.03%180亿 USD0.06%US$111.77-0.45%
iShares Biotechnology ETFIBB461.34万0.04%107.38亿 USD0.44%US$200.02-2.08%
Schwab U.S. Small-Cap ETFSCHA368.17万0.02%217.13亿 USD0.03%US$32.56-0.31%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
